Recent advances in the detection of prostate cancer using epigenetic markers in commonly collected laboratory samples

Laboratory Medicine

Volumn 40, Issue 3, 2009, Pages 171-178

  Maxwell, Adam ^a   McCudden, Christopher R ^a   Wians, Frank ^b   Willis, Monte S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLCYTOSINE; ADENOSYLHOMOCYSTEINASE; APC PROTEIN; CALVASCULIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOSINE; DNA METHYLTRANSFERASE; GLUTATHIONE TRANSFERASE P1; GUANINE; HISTONE DEACETYLASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; S ADENOSYLMETHIONINE; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RARBETA2; TUMOR MARKER; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

BLOOD ANALYSIS; CANCER DIAGNOSIS; CPG ISLAND; DIAGNOSTIC ACCURACY; DNA DETERMINATION; DNA METHYLATION; DNA SEQUENCE; EARLY DIAGNOSIS; EPIGENETICS; GENE SILENCING; GENETIC MARKER; HUMAN; LABORATORY TEST; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROSTATE CANCER; REVIEW; SAMPLING; URINALYSIS;

EID: 77951959307     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LMMY5RHJL9UD6RGS     Document Type: Review

References (40)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. McDavid K, Lee J, Fulton JP, et al. Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep. 2004;119:174-186.
3. Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett. 2007;249:30-39.
4. Hayes RB, Reding D, Kopp W, et al. Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21:349S-355S.
5. Roobol MJ, Kirkels WJ, Schroder FH. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int. 2003;92 Suppl 2:48-54.
6. Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000;88:2398-2424.
7. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350:2239-2246.
8. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ. 2007;176:1853-1858. (Pubitemid 46999868)
9. Catalona WJ. Management of cancer of the prostate. N Engl J Med. 1994;331:996-1004.
10. Wang X. Autoantibody biomarkers in prostate cancer. Lab Med 2008;39:165-171.
11. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457-463.
12. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415-428.
13. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA. 1994;91:11733-11737.
14. Lin X, Tascilar M, Lee WH, et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol. 2001;159:1815-1826.
15. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30:445-600. (Pubitemid 26016466)
16. Nan X, Meehan RR, Bird A. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucleic Acids Res. 1993;21:4886-4892.
17. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl- CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998;393:386-389.
18. Goessl C, Krause H, Muller M, et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 2000;60:5941-5945.
19. Lee WH, Isaacs WB, Bova GS, et al. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: A new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prev. 1997;6:443-450.
20. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-9826. (Pubitemid 26296693)
21. Goessl C, Muller M, Heicappell R, et al. DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann NY Acad Sci. 2001;945:51-58. (Pubitemid 33022431)
22. Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology. 2002;60:1131-1135.
23. Gonzalgo ML, Pavlovich CP, Lee SM, et al. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res. 2003;9:2673-2677.
24. Hoque MO, Topaloglu O, Begum S, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol. 2005;23:6569-6575.
25. Nakayama M, Gonzalgo ML, Yegnasubramanian S, et al. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem. 2004;91:540-552.
26. Nakayama M, Bennett CJ, Hicks JL, et al. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: A detailed study using laser-capture microdissection. Am J Pathol. 2003;163:923-933. (Pubitemid 37040128)
27. Katz AE, Olsson CA, Raffo AJ, et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology. 1994;43:765-775.
28. Moreno JG, Croce CM, Fischer R, et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res. 1992;52:6110-6112.
29. Shariat SF, Gottenger E, Nguyen C, et al. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Cancer Res. 2002;62:5974-5979.
30. Papadopoulou E, Davilas E, Sotiriou V, et al. Cell-free DNA and RNA in plasma as a new molecular marker for prostate and breast cancer. Ann NY Acad Sci. 2006;1075:235-243.
31. Reibenwein J, Pils D, Horak P, et al. Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance. Prostate. 2007;67:427-432. (Pubitemid 46341084)
32. Bastian PJ, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res. 2005;11:4097-4106.
33. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004;64:1975-1986.
34. Ellinger J, Bastian PJ, Jurgan T, et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology. 2008;71:161-167.
35. Ellinger J, Haan K, Heukamp LC, et al. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate. 2008;68:42-49.
36. Cairns P, Esteller M, Herman JG, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res. 2001;7:2727-2730. (Pubitemid 32911377)
37. Topaloglu O, Hoque MO, Tokumaru Y, et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res. 2004;10:2284-2288. (Pubitemid 38445685)
38. Roupret M, Hupertan V, Yates DR, et al. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res. 2007;13:1720-1725.
39. Woodson K, O'Reilly KJ, Hanson JC, et al. The usefulness of the detection of GSTP1 methylation in urine as a biomarker in the diagnosis of prostate cancer. J Urol. 2008;179:508-511; discussion 511-512.
40. Roupret M, Hupertan V, Catto JW, et al. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer. 2008;122:952-956.